MDACC Study No:2013-0141 ( NCT No: NCT01828346)
Title:A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination with 5-azacitidine in Subjects with Myelodysplastic Syndrome who are Naive, Refractory or have Relapsed to 5-azacitidine Therapy
Principal Investigator:Gautam Borthakur
Treatment Agent:5-Azacytidine; Birinapant
Study Status:Closed
Study Description:The goal of this clinical research study is to find the dose of birinapant that
is safe and tolerated when given with azacitidine to patients who have not
taken azacitidine before, or who have MDS that did not respond to azacitidine
or has relapsed after taking azacitidine. Pharmacodynamic (PD) testing will
also be done. PD testing measures how the level of study drug in your body may
affect the disease.

Birinapant is designed to remove certain proteins in cancer cells, which may
cause the cancer cells to die.

Azacitidine is designed to block certain proteins in cancer cells whose job is
to stop the function of the tumor-fighting proteins. By blocking the "bad"
proteins, the tumor-fighting proteins may be able to work better.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:5-Azacytidine
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:TetraLogic Pharmaceuticals
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Gautam Borthakur
For Clinical Trial Enrollment:713-563-1586
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults